可手术乳腺癌围手术辅助化疗远期疗效观察  

Long Term Effect of Perioperative Chemotherapy in Breast Cancer

作　　者：石松魁[1] 刘俊田[1] 宁连胜[1] 李云英[1] 马淑资[1] 郎义方[1] 

机构地区：[1]天津市肿瘤医院乳腺科,天津市300060

出　　处：《中国肿瘤临床》1997年第9期665-668,共4页Chinese Journal of Clinical Oncology

摘　　要：自1971年7月～1982年12月应用秋水仙硷制剂和CU方案围手术辅助治疗乳腺癌420例。总的10年以上生存率为56％，其中有效组（CR＋PR）与无效组（SD＋PD）分别为71％及48．6％（P＝0．00001）。肿瘤对本前化疗药物越敏感预后越好，其中CR组经病理证实腋淋巴结转移率仅30％，局部欠发率为5％，10年以上生存率达到了85％。作者认为乳腺癌的因手术辅助化疗，尤其是术前有效药物的化疗对改善预后有较好的效果。From July 1971 to December 1982, 420 operated cases of breast cancer received colchicine plus uraphetine as a perioperative adjuvant chemotherapy. The overall 10-year survival rate was 56%. The same rates in the responded group and the non-responded group were 71% and 48. 6% respectively (P=0. 00001). The more pronounced the tumor responded to chemotherapy, the better the prognosis was. The rate of involvement of the axillary lymph node in the CR group was 30% and the local recurrent rate was 5%. The 10-year survival rate of this series was 85%. The authors suggest that the perioperative chemotherapy of breast cancer as an adjuvant therapy may be helpful to improve the long term outcome of the patient.

关 键 词：乳腺肿瘤 围手术期 药物疗法 远期疗效 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]